Search

everythinglearnresearchcommunity

for

Search:↓

There is no new information on pp405, with data collection expected to finish by the end of 2025. Users are discussing the timeline for data analysis and completion of Pelage Pharmaceuticals' phase 2 study.

Hair loss treatments, specifically about the effectiveness of RU58841 compared to Pyrilutamide. Molecular weights and side effects were discussed in terms of efficacy and cost-effectiveness.

The user experienced severe hair shedding despite using oral finasteride, minoxidil, dutasteride, and RU58841, and was diagnosed with Non-Alcoholic Fatty Liver Disease (NAFLD). They are considering switching to topical treatments due to the ineffectiveness of their current regimen.

The effects of Pyrilutamide, a hair loss treatment that is being tested for June/July; and reports from people who have experienced side effects similar to those of RU58841, suggesting they may have been sold an incorrect product from their supplier.

A user's regimen to help with their diffuse thinning, which includes taking Pyrilutamide BID, 1mg finasteride daily, 2.5mg oral minoxidil daily, topical minoxidil since August 2021, LLLT every two days, topical fin, progesterone, melatonin, minoxidil (started one week ago), pumpkin seed oil and not dermarolling; other commenters suggested Nizoral for dandruff control and caution when using pre-mixed products with Pyrilutamide.

Treatments for hair loss, including Minoxidil, finasteride, and RU58841. The post discusses the potential benefits of Pyrilutamide compared to RU58841 in terms of strength and longevity.

The user is using Minoxidil, Finasteride, RLLT, Nizoral Shampoo, and microneedling for hair regrowth. They notice some thickening and new hair growth, especially in the front, but are unsure about the overall regrowth due to previous head shaving and photo comparisons.

The conversation discusses the potential role of prolactin in hair loss and mentions treatments like HMI115, mucuna pruriens, Zinc, and B6 P5P for lowering prolactin levels. It also touches on the use of natural compounds and the lack of studies due to funding issues.

A 33-year-old woman experienced significant hair loss and found relief using Mary Ruth’s liquid morning multivitamin + hair growth and Nioxin shampoo and conditioner. She noticed reduced shedding and longer hair growth after three months of use.

A 22-year-old has been using minoxidil and finasteride for four years with limited success and recently added microneedling to their regimen. They have seen some hair regrowth and are advised to continue using minoxidil alongside microneedling and consider lifestyle factors like diet and stress.

Breezula passed a clinical trial in August and there are questions about its availability in 2021 and potential delays due to Covid. No specific treatments were discussed.

A user's experience with treating their hair loss using finasteride, minoxidil, RU58841, dermarolling, and nizoral; specifically discussing dosage levels of the medications and effects on libido.

The conversation is about using Xeljanz for hair regrowth in individuals with LPP. The user is seeking experiences and expectations from others who have tried this treatment.

The conversation discusses the use of vasodilators like Minoxidil, L-arginine, and Niacin for hair regrowth, with Minoxidil causing intolerable side effects for the original poster. It also highlights that certain medications, including Lisinopril, antidepressants, and statins, can cause hair loss.

Lactic acid is not effective for hair growth when applied topically. JXL069, finasteride, and minoxidil are suggested as alternative treatments.

Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.

Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.

An update on the use of Pyrilutamide, a new drug for hair loss, which has resulted in no shedding or testicle ache; other users have questioned the science behind this and shared their own experiences with Finasteride, Minoxidil, and microneedling.

User shared progress of two years using 1mg daily Finasteride and 2x weekly microneedling for hair loss. Many users praised the results and discussed their own experiences with microneedling and Finasteride.

A user reported positive hair growth using a regimen of oral finasteride, minoxidil, Dr. Pen, keto shampoo, and a Capillus 272 LLLT cap. Other users debated the effectiveness of the LLLT cap, with some attributing the success to the combined treatments rather than the cap alone.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

The conversation humorously discusses hair loss treatments, including finasteride, dutasteride, minoxidil, and microneedling. The user shares progress and thanks the pharmaceutical industry, with comments on the effectiveness and side effects of these treatments.

A 10 month update on the effectiveness of a hair loss treatment regimen involving minoxidil, finasteride, dermarolling and nizoral. Questions were asked about using minoxidil alone, dermaroller length, age, and when results were seen.

RU58841 should be refrigerated. The KB Solution is more effective at delivering RU58841 to the scalp.

A user shared their successful hair loss treatment using 1.25mg finasteride daily, 2.5mm microneedling every 1-3 weeks, zinc pyrithione shampoo, occasional scalp massages, and 40% glycolic acid on temples. They reported significant progress over 21 months.

The conversation discusses a hair loss treatment regimen involving minoxidil, finasteride, RU58841, JXL069, and nizoral shampoo. The user reports seeing new black dots in areas where hair hasn't grown in years, suggesting potential regrowth.

The conversation is about the delay in receiving updates on the HMI-115 phase 1 trial for hair loss. No specific treatments are mentioned in the conversation.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

The conversation is about finding a reasonably priced shampoo with piroctone olamine in the US. The user is cautious about trying new or smaller brands.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.